NASDAQ: VCNX - Vaccinex, Inc.

Rentabilidade por seis meses: -72.6%
Rendimento de dividendos: 0.00%
Setor: Healthcare

Cronograma de promoção Vaccinex, Inc.


Sobre a empresa Vaccinex, Inc.

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. Its Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease.

mais detalhes
It has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. The company was incorporated in 2001 and is headquartered in Rochester, New York.

IPO date 2018-08-09
ISIN US9186401033
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.vaccinex.com
Цена ао 0.61
Alteração de preço por dia: +52.7% (0.61)
Alteração de preço por semana: +63.42% (0.57)
Alteração de preço por mês: -26.65% (1.27)
Alteração de preço em 3 meses: -14.54% (1.09)
Mudança de preço em seis meses: -72.6% (3.4)
Mudança de preço por ano: -87.43% (7.41)
Mudança de preço em 3 anos: -33.94% (1.41)
Mudança de preço em 5 anos: -82.36% (5.28)
Mudança de preço desde o início do ano: -4.95% (0.98)

Subestimação

Nome Significado Nota
P/S 8.37 1
P/BV -2.06 0
P/E 0 0
EV/EBITDA -0.153 0
Total: 3.88

Eficiência

Nome Significado Nota
ROA, % -557.73 0
ROE, % 876.29 10
Total: 3.33

Dividendos

Nome Significado Nota
Div yield, % 0 0
DSI 0 0
Total: 0

Obrigação

Nome Significado Nota
Debt/EBITDA -0.0108 10
Total: 10

Impulso de crescimento

Nome Significado Nota
Rentabilidade Revenue, % 8.99 2
Rentabilidade Ebitda, % -37.51 0
Rentabilidade EPS, % 1654.11 10
Total: 2.4



Supervisor Cargo Pagamento Ano de nascimento
Dr. Maurice Zauderer Ph.D. Co-Founder, CEO, President & Director 411.7k 1946 (79 anos)
Dr. Elizabeth E. Evans Ph.D. COO and Senior VP of Discovery & Translational Medicine 291.57k 1973 (52 ano)
Dr. Ernest S. Smith Ph.D. Senior VP of Research & Chief Scientific Officer 297.25k 1972 (53 ano)
Dr. John E. Leonard Ph.D. Senior Vice President of Development N/A 1947 (78 anos)
Ms. Jill Sanchez CPA Chief Financial Officer N/A 1972 (53 ano)

Endereço: United States, Rochester. NY, 1895 Mount Hope Avenue - abrir no Google Maps, abrir mapas Yandex
Site: https://www.vaccinex.com